Results and Reports. Scriptgen shall provide to Lilly written bi-monthly reports which describes the results and progress of the Project. Upon completion of the Project or termination of this Agreement, Scriptgen shall promptly provide Lilly with a comprehensive written final report describing the results of the Project with respect to each Target Protein including, but not limited to, an [***] for all Successful Compounds (the "Final Comprehensive Report"). A Final Comprehensive Report shall not be complete unless, to the extent commercially reasonably possible, the structures of Scriptgen Compounds that are Successful Compounds are revealed and confirmed in such report and, in any event, notwithstanding Scriptgen's commercially reasonable efforts, if Scriptgen Compounds are the only Successful Compounds identified in the Project, at least the structure of one such compound must be revealed and confirmed in such report (Scriptgen shall have the primary responsibility for identifying the structure of such compounds, however, Lilly hereby agrees to provide reasonable assistance to Scriptgen with respect to identifying the structure of such compounds). Furthermore, Scriptgen shall use its best efforts to provide Lilly with reference samples [***] of all Successful Compounds that were not furnished by Lilly for purposes of the Project. These reference samples shall be provided to Lilly in sufficient quantity so as to enable Lilly to reasonably replicate such Successful Compounds for development and other purposes as it may deem appropriate. Scriptgen shall also reasonably cooperate with Lilly in transferring Scriptgen's Know-how and other information related to the Successful Compounds to the extent provided in Article V and subject to the provisions of Article VIII.
Appears in 2 contracts
Sources: Atlas Screen Agreement (Scriptgen Pharmaceuticals Inc), Atlas Screen Agreement (Scriptgen Pharmaceuticals Inc)